September 21-25 is Global ITP Awareness Week: Spreading Rare Disease Awareness
source: pixabay.com

September 21-25 is Global ITP Awareness Week: Spreading Rare Disease Awareness

In 2020, September 21-25 will be recognized as Global Immune Thrombocytopenia (ITP) Awareness Week. The week will aim to help spread awareness about ITP around the world both in the…

Continue Reading September 21-25 is Global ITP Awareness Week: Spreading Rare Disease Awareness
The Results From This Immune Thrombocytopenia Trial are Good News for Patients
source: pixabay.com

The Results From This Immune Thrombocytopenia Trial are Good News for Patients

According to a story from ucb.com, the biopharmaceutical company UCB has recently released the final results from its phase 2 clinical trial which tested the company's investigational monoclonal antibody rozanolixizumab…

Continue Reading The Results From This Immune Thrombocytopenia Trial are Good News for Patients
Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
kalhh / Pixabay

Experimental Treatment for Immune Thrombocytopenia Begins Trials in China

According to a story from uk.finance.yahoo.com, the company Hutchison China MediTech Limited ("Chi-Med") has recently kicked off a phase 1 clinical trial. This trial is testing the company's investigational drug…

Continue Reading Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
frolicsomepl / Pixabay

Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy

According to a story from Market Screener, an analysis of real-world data (data gathered outside of the clinical setting) suggests that the drug eltrombopag, marketed as Revolade, offers substantial advantages…

Continue Reading Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
Experimental Treatment for ITP Gets Orphan Drug Designation
mohamed_hassan / Pixabay

Experimental Treatment for ITP Gets Orphan Drug Designation

According to a story from financialbuzz.com, the biopharmaceutical company Principia Biopharma recently announced that its experimental medical product PRN1008 has received Orphan Drug designation from the US Food and Drug…

Continue Reading Experimental Treatment for ITP Gets Orphan Drug Designation